Back Samols, E, Marri, G, Marks, V (1965) Promotion of insulin secretion by glucagon, Lancet , 40, 415-6
Not catastrophically, but measurably
Clinical guidance suggests starting with manufacturer recommendations as outlined in FDA labeling, then adjusting based on individual response
Additionally, the FDA generally prohibits the individual importation of prescription biologics like GLP-1s due to safety and temperature control concerns
A patient can lose as much as 20% of their body fat after a year on the drugs a powerful weapon in the fight against the obesity epidemic
Pretreatment with each examined GLP-1 analogs, including GLP-1(736), liraglutide, and exendin-4, led to significantly reduced Ca 2+ responses (by 53.8%, 58.1%, and 72.2%, respectively)